Purpose. To investigate the excretion of irinotecan hydrochloride (CPT-11) and its active
metabolite, SN-38, into the gastrointestinal lumen via the biliary and/or intestinal membrane …

PURPOSE: The aim of this study was to investigate the excretion of irinotecan hydrochloride
(CPT-11) and its metabolites into the gastrointestinal lumen via the biliary route after …

Abstract Irinotecan (CPT‐11) and its active metabolite, 7‐ethyl‐10‐hydroxycamptothecin
(SN‐38), are believed to be reabsorbed by intestinal cells and to enter the entero‐hepatic …

Abstract Irinotecan (CPT‐11) is a semisynthetic derivative of camptothecine that has proved
activity in the treatment of colorectal carcinoma. The metabolites identified in humans …

This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after iv
infusion of 125 mg/m2 (100 μCi)[14C] CPT-11 in eight patients with solid tumors. Mean±SD …

Irinotecan (CPT-11) and its main metabolite SN-38 are potent anticancer derivatives of
camptothecin (CPT), with active lactone and inactive carboxylate forms coexisting. A simple …

A sensitive high-performance liquid chromatographic (HPLC) method has been developed
and validated for the determination of the lactone and carboxylate forms of the novel …

Two patients were treated with CPT-11 for colorectal cancer and had a percutaneous biliary
catheter for extrahepatic biliary obstruction. The first patient was treated with CPT-11 …

Abstract Irinotecan (CPT-11) is a new drug active in colorectal cancer. A comparison was
made of the efficacy and pharmacokinetics of CPT-11 after ip versus iv administration to …

One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …